Table 1. Baseline Characteristics of Systolic Blood Pressure Intervention Trial Participants Included in the Current Analysis by Treatment Group and Race and Ethnicity.
Variable | Treatment Group, No. (%) | |||||
---|---|---|---|---|---|---|
Standard (n = 4141) | Intensive (n = 4415) | |||||
Non-Hispanic White (n = 2451) | Non-Hispanic Black (n = 1306) | Hispanic (n = 384) | Non-Hispanic White (n = 2639) | Non-Hispanic Black (n = 1329) | Hispanic (n = 447) | |
Age, median (IQR), y | 70 (63-77) | 63 (57-70)a | 64 (58-72)a | 70 (64-77) | 62 (57-71)a | 64 (58-72)a |
Sex | ||||||
Male | 1760 (72) | 714 (55) | 200 (52) | 1861 (71) | 721 (54) | 249 (56) |
Female | 691 (28) | 592 (45)a | 184 (48)a | 778 (29) | 608 (46)a | 198 (44)a |
High school level of education or less | 2007 (82) | 846 (65)a | 227 (59)a | 2153 (82) | 852 (64)a | 267 (60)a |
Full-time employment | 513 (21) | 275 (21) | 89 (23) | 538 (20) | 279 (21) | 116 (26) |
Retired | 1614 (66) | 669 (51)a | 200 (52)a | 1766 (67) | 682 (51)a | 226 (51)a |
Lives with others | 1793 (73) | 849 (65)a | 295 (77)a | 1938 (73) | 853 (64)a | 334 (75)a |
Health insurance status | ||||||
Uninsured | 155 (6) | 235 (18)a | 40 (10)a | 142 (5) | 255 (19)a | 63 (14)a |
Medicare or Medicaid | 1580 (64) | 632 (48)a | 197 (51)a | 1725 (65) | 592 (45)a | 224 (50)a |
Private | 1090 (44) | 471 (36)a | 175 (46)a | 1237 (47) | 486 (37)a | 190 (43)a |
VA | 583(24) | 217 (17)a | 34 (9)a | 642 (24) | 224 (17)a | 50 (11)a |
Usual source of care | ||||||
No usual source | 88 (4) | 60 (5)a | 17 (4)a | 82 (3) | 64 (5)a | 24 (5)a |
Hospital or clinic | 2144 (88) | 1028 (79) | 340 (89) | 2324 (88) | 1037 (78) | 388 (87) |
Community health center | 210 (9) | 215 (17) | 27 (7) | 231 (9) | 225 (17) | 35 (8) |
Smoking status | ||||||
Never | 1007 (41) | 577 (44)a | 235 (61)a | 1096 (42) | 582 (44)a | 246 (55)a |
Current | 217 (9) | 286 (22) | 33 (9) | 234 (9) | 312 (23) | 64 (14) |
Former | 1227 (50) | 443 (34) | 116 (30) | 1309 (50) | 435 (33) | 137 (31) |
BMI, median (IQR) | 29 (26-32) | 30 (27-34)a | 28 (26-31)a | 29 (26-32) | 30 (27-35)a | 29 (26-33)a |
SBP, median (IQR), mm Hg | 139 (130-149) | 139 (130-150) | 141 (132-151) | 139 (130-149) | 138 (128-150) | 140 (131-150) |
eGFR, median (IQR), mL/min/1.73 m2 | 68 (56-79) | 77 (62-91)a | 77 (63-89)a | 68 (56-80) | 76 (61-91)a | 77 (64-91)a |
Serum potassium, median (IQR), mmol/L | 4 (4-4) | 4 (4-4)a | 4 (4-4)a | 4 (4-4) | 4 (4-4)a | 4 (4-4)a |
Serum sodium, median (IQR), mEq/L | 140 (139-142) | 141 (139-142)a | 140 (139-142)a | 140 (139-142) | 141 (139-142)a | 141 (139-142)a |
Depression | 455 (19) | 225 (17) | 79 (21) | 494 (19) | 222 (17) | 90 (20) |
No. of antihypertensive medications, median (IQR) | 2 (1-3) | 2 (1-3)a | 2 (1-2)a | 2 (1-3) | 2 (1-3)a | 2 (1-3)a |
mTIS, median (IQR) | 1 (0-2) | 1 (1-2)a | 1 (0-2)a | 1 (1-2) | 2 (1-2)a | 1 (1-2)a |
ACEI or ARB | 1468 (60) | 686 (53)a | 247 (64)a | 1560 (59) | 734 (55)a | 297 (66)a |
CCB | 764 (31) | 614 (47)a | 130 (34)a | 839 (32) | 581 (44)a | 136 (30)a |
Thiazide diuretic | 970 (40) | 671(51)a | 118 (31)a | 944 (36) | 642 (48)a | 159 (36)a |
Loop diuretic | 132 (5) | 78 (6) | 16 (4) | 153 (6) | 92 (7) | 15 (3) |
Beta-blocker | 924 (38) | 424 (32)a | 119 (31)a | 1041 (39) | 460 (35)a | 153 (34)a |
Alpha-blocker | 272 (11) | 101 (8)a | 28 (7)a | 310 (12) | 108 (8)a | 33 (7)a |
No. of non-antihypertensive medications, median (IQR) | 3 (1-6) | 2 (1-5)a | 2 (1-4)a | 4 (2-6) | 3 (1-5)a | 2 (1-4)a |
Current medication use | ||||||
Statin | 1221 (50) | 459 (35)a | 153 (40)a | 1288 (49) | 420 (32)a | 171 (38)a |
Aspirin | 1439 (59) | 564 (43)a | 150 (39)a | 1622 (61) | 567 (43)a | 177 (40)a |
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate; mTIS, modified therapeutic intensity score; SBP, systolic blood pressure; VA, Veterans Affairs.
Indicates statistically significant difference from non-Hispanic White participants (P < .05).